The DR Barometer Program aims to improve the vision health of adults living with diabetes around the world. This collaborative program was initiated with the DR Barometer Study, which identified serious gaps in awareness and education of diabetic eye diseases, as well as barriers to screening and treatment services at a country level that require urgent attention.
To address these gaps and promote forward action, the DR Barometer Program brings together key stakeholders (including patients, ophthalmologists, diabetes specialists, primary care providers, diabetes educators, governments, and industry) to establish and maintain a global community. This multidisciplinary community will help foster collaboration and knowledge exchange and therein help influence and shape health systems capacity to support adults with diabetes to maintain and improve their vision health.
The IFA is an international non-governmental organization (NGO) with a membership base comprising government, NGOs, industry, academia and individuals in 70 countries. IFA is a voice alongside and on behalf of older adults globally and has General Consultative Status at the United Nations and its agencies including the World Health Organization.
The IAPB was established in 1975 as a coordinating, umbrella organisation to lead international efforts in blindness prevention activities. Its first major achievement was to promote the establishment of a WHO programme for prevention of blindness, with which it has remained strongly linked, and which is now embodied in the global initiative, VISION 2020: The Right to Sight.
The IDF is an umbrella organization of over 230 national diabetes associations in 170 countries and territories. It represents the interests of the growing number of people with diabetes and those at risk of developing the disease. The Federation has been leading the global diabetes community since 1950.
Bayer is a global enterprise with a focus on the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. The Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen.